Media headlines about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have trended somewhat positive on Sunday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spring Bank Pharmaceuticals earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.1529811290376 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Spring Bank Pharmaceuticals (SBPH) Proposed Public Offering of Common Stock (streetinsider.com)
- Spring Bank Pharmaceuticals announces pricing of common stock (seekingalpha.com)
- Spring Bank Pharmaceuticals readies common stock offering (seekingalpha.com)
- Spring Bank Announces Proposed Public Offering of Common Stock (finance.yahoo.com)
- B. Riley Comments on Spring Bank Pharmaceuticals Inc’s FY2022 Earnings (SBPH) (americanbankingnews.com)
Separately, Cantor Fitzgerald set a $32.00 price objective on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 9th.
Shares of SBPH stock traded down $0.27 during trading hours on Friday, hitting $12.03. The stock had a trading volume of 87,635 shares, compared to its average volume of 63,473. The company has a market capitalization of $162.18 million, a P/E ratio of -6.43 and a beta of -0.12. Spring Bank Pharmaceuticals has a twelve month low of $10.81 and a twelve month high of $18.93.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last issued its quarterly earnings results on Thursday, August 2nd. The company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.22. equities research analysts expect that Spring Bank Pharmaceuticals will post -1.93 EPS for the current fiscal year.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.